Recombinant Plasma Protein Therapeutics Market Size by Drug Class, Cell Line, Indication, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2032
5.3%
CAGR (2026-2032)
16.42 USD Bn.
Market Size
310
Report Pages
139
Market Tables
Overview
The Recombinant Plasma Protein Therapeutics Market size was valued at USD 16.42 Billion in 2025 and the total Recombinant Plasma Protein Therapeutics revenue is expected to grow at a CAGR of 5.3% from 2025 to 2032, reaching nearly USD 23.57 Billion by 2032.
Plasma-derived therapies and their recombinant analogs, collectively referred to plasma protein therapies, biologic medicines, and chemical medicines, because production begins with plasma as a biological starting material. Each therapy has its unique biochemical profile, which effects in different clinical responses and efficiency among patients. A numeral of plasma proteins is also produced using recombinant gene technologies, in which the protein is produced from an expression system into which a gene has been presented.
To know about the Research Methodology :- Request Free Sample Report
The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The global recombinant plasma protein therapeutics market primary is driven by various factors such as change from use of plasma-derived proteins to recombinant therapies. Furthermore, increase in the amount of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid implementation of genetic causing technologies in healthcare for the development of new therapeutics are also estimated to fuel the market.
However, the high cost of treatment and availability of different therapies are expected to restrain the global market. Furthermore, an increase in the investment in research and technology is measured as a major opportunity for the growth of the global recombinant plasma protein therapeutics market.
The report covers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2025 to 2032.
Based on the drug class, the recombinant coagulation factor VIII segment expected to dominate the xx% market share during the forecast period. It has completely replaced human blood plasma-derived proteins and desmopressin in treating a severe and mild form of hemophilia A. Improvements in recombinant technology coagulation factor VIII are organization a platform for novel therapeutic possibilities in patients with hemophilia. The development of turoctocog alfa, third-generation, B-domain truncated recombinant FVIII, has been produced and formulated without the use of human serum-derived components.
By Indication the, hemophilia A segment is held to dominate the xx% market share during the forecast period. High prevalence rate and occurrence of simple form in 70% detected patient’s purposes of its market. Hemophilia A can be mild, moderate, depending on how little you have of factor VIII.
Regionally, North America is expected to account for the largest share of the recombinant plasma protein therapeutics market during the forecast period. The major factors influencing its market growth are the rising prevalence of hemophilia A and the existence of a comprehensive network of federally funded hemophilia treatment centers. North America controlled the market owing to the presence of a large patient base and availability of well-developed infrastructure for storing and maintaining high-quality source plasma are major factors dynamic the growth of the market.
The objective of the report is to present comprehensive analysis of global Recombinant Plasma Protein Therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding global Recombinant Plasma Protein Therapeutics market dynamics, structure by analyzing the market segments, and project the global Recombinant Plasma Protein Therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global Recombinant Plasma Protein Therapeutics market make the report investor’s guide.
Global Recombinant Plasma Protein Therapeutics Market Scope: Inquire before buying
| Recombinant Plasma Protein Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 16.42 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 5.3% | Market Size in 2032: | USD 23.57 Bn. |
| Segments Covered: | by Drug Class | Recombinant Coagulation Factors Recombinant Coagulation Factor VIII Recombinant Coagulation Factor IX Recombinant Coagulation Factor VIIa Others Human C1 Esterase Inhibitor |
|
| by Cell Line | Chinese Hamster Ovary (CHO) Cell Line Baby Hamster Kidney (BHK) Cell Line Human Embryonic Kidney (HEK) Cell Line Others |
||
| by Indication | Hemophilia A Hemophilia B Von Willebrand Disease Others |
||
Global Recombinant Plasma Protein Therapeutics Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
South America (Brazil, Argetina and Rest of South America)
Global Recombinant Plasma Protein Therapeutics Market, Key players
1. CSL Limited
2. Shire Takeda Pharmaceutical Company Limited
3. Octapharma
4. Novo Nordisk A/S
5. Bayer AG
6. Bioverativ Therapeutics
7. Aptevo Therapeutics
8. Pharming Group NV
9. Pfizer Inc.
10. Ferring B.V.
11. Baxter
12. HEMA Biologics, LLC
13. OPKO Health, Inc
14. Sinocelltech Ltd
Frequently Asked Questions:
1. Which region has the largest share in Global Recombinant Plasma Protein Therapeutics Market?
Ans: North America region holds the highest share in 2025.
2. What is the growth rate of Global Recombinant Plasma Protein Therapeutics Market?
Ans: The Global market is growing at a CAGR of 5.3% during forecasting period 2026-2032.
3. What is scope of the Global Recombinant Plasma Protein Therapeutics market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global market?
Ans: The important key players in the Global market are – CSL Limited, Shire Takeda Pharmaceutical Company Limited, Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Aptevo Therapeutics, Pharming Group NV, Pfizer Inc., Ferring B.V., Baxter, HEMA Biologics, LLC, OPKO Health, Inc, and Sinocelltech Ltd.
5. What is the study period of this market?
Ans: The Global market is studied from 2025 to 2032.
Table of Contents
Global Recombinant Plasma Protein Therapeutics Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Recombinant Plasma Protein Therapeutics Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
6.1. Global Recombinant Plasma Protein Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
7.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Drug Class
7.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class
8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line
8.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Cell Line
8.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Cell Line
8.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line
9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
9.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Indication
9.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Indication
9.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication
10. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Region
10.1. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Region
10.2. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Region
10.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Region
11. North America Recombinant Plasma Protein Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Recombinant Plasma Protein Therapeutics Market Overview
11.3. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
11.4. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
11.4.1. Recombinant Coagulation Factors
11.4.1.1. Recombinant Coagulation Factor VIII
11.4.1.2. Recombinant Coagulation Factor IX
11.4.1.3. Recombinant Coagulation Factor VIIa
11.4.1.4. Others
11.4.2. Human C1 Esterase Inhibitor
11.5. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line
11.6. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
11.6.1. Chinese Hamster Ovary (CHO) Cell Line
11.6.2. Baby Hamster Kidney (BHK) Cell Line
11.6.3. Human Embryonic Kidney (HEK) Cell Line
11.6.4. Others
11.7. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
11.8. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
11.8.1. Hemophilia A
11.8.2. Hemophilia B
11.8.3. Von Willebrand Disease
11.8.4. Others
11.9. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country
11.10. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Recombinant Plasma Protein Therapeutics Market Analysis, by Country
11.12. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
11.12.1. Recombinant Coagulation Factors
11.12.1.1. Recombinant Coagulation Factor VIII
11.12.1.2. Recombinant Coagulation Factor IX
11.12.1.3. Recombinant Coagulation Factor VIIa
11.12.1.4. Others
11.12.2. Human C1 Esterase Inhibitor
11.13. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
11.13.1. Chinese Hamster Ovary (CHO) Cell Line
11.13.2. Baby Hamster Kidney (BHK) Cell Line
11.13.3. Human Embryonic Kidney (HEK) Cell Line
11.13.4. Others
11.14. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
11.14.1. Hemophilia A
11.14.2. Hemophilia B
11.14.3. Von Willebrand Disease
11.14.4. Others
11.15. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
11.15.1. Recombinant Coagulation Factors
11.15.1.1. Recombinant Coagulation Factor VIII
11.15.1.2. Recombinant Coagulation Factor IX
11.15.1.3. Recombinant Coagulation Factor VIIa
11.15.1.4. Others
11.15.2. Human C1 Esterase Inhibitor
11.16. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
11.16.1. Chinese Hamster Ovary (CHO) Cell Line
11.16.2. Baby Hamster Kidney (BHK) Cell Line
11.16.3. Human Embryonic Kidney (HEK) Cell Line
11.16.4. Others
11.17. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
11.17.1. Hemophilia A
11.17.2. Hemophilia B
11.17.3. Von Willebrand Disease
11.17.4. Others
11.18. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Cell Line
11.18.3. By Indication
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Recombinant Plasma Protein Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Recombinant Plasma Protein Therapeutics Market Overview
12.3. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
12.4. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.4.1. Recombinant Coagulation Factors
12.4.1.1. Recombinant Coagulation Factor VIII
12.4.1.2. Recombinant Coagulation Factor IX
12.4.1.3. Recombinant Coagulation Factor VIIa
12.4.1.4. Others
12.4.2. Human C1 Esterase Inhibitor
12.5. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line
12.6. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.6.1. Chinese Hamster Ovary (CHO) Cell Line
12.6.2. Baby Hamster Kidney (BHK) Cell Line
12.6.3. Human Embryonic Kidney (HEK) Cell Line
12.6.4. Others
12.7. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
12.8. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.8.1. Hemophilia A
12.8.2. Hemophilia B
12.8.3. Von Willebrand Disease
12.8.4. Others
12.9. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country
12.10. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Recombinant Plasma Protein Therapeutics Market Analysis, by Country
12.12. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.12.1. Recombinant Coagulation Factors
12.12.1.1. Recombinant Coagulation Factor VIII
12.12.1.2. Recombinant Coagulation Factor IX
12.12.1.3. Recombinant Coagulation Factor VIIa
12.12.1.4. Others
12.12.2. Human C1 Esterase Inhibitor
12.13. Germany Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.13.1. Chinese Hamster Ovary (CHO) Cell Line
12.13.2. Baby Hamster Kidney (BHK) Cell Line
12.13.3. Human Embryonic Kidney (HEK) Cell Line
12.13.4. Others
12.14. Germany Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.14.1. Hemophilia A
12.14.2. Hemophilia B
12.14.3. Von Willebrand Disease
12.14.4. Others
12.15. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.15.1. Recombinant Coagulation Factors
12.15.1.1. Recombinant Coagulation Factor VIII
12.15.1.2. Recombinant Coagulation Factor IX
12.15.1.3. Recombinant Coagulation Factor VIIa
12.15.1.4. Others
12.15.2. Human C1 Esterase Inhibitor
12.16. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.16.1. Chinese Hamster Ovary (CHO) Cell Line
12.16.2. Baby Hamster Kidney (BHK) Cell Line
12.16.3. Human Embryonic Kidney (HEK) Cell Line
12.16.4. Others
12.17. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.17.1. Hemophilia A
12.17.2. Hemophilia B
12.17.3. Von Willebrand Disease
12.17.4. Others
12.18. France Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.18.1. Recombinant Coagulation Factors
12.18.1.1. Recombinant Coagulation Factor VIII
12.18.1.2. Recombinant Coagulation Factor IX
12.18.1.3. Recombinant Coagulation Factor VIIa
12.18.1.4. Others
12.18.2. Human C1 Esterase Inhibitor
12.19. France Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.19.1. Chinese Hamster Ovary (CHO) Cell Line
12.19.2. Baby Hamster Kidney (BHK) Cell Line
12.19.3. Human Embryonic Kidney (HEK) Cell Line
12.19.4. Others
12.20. France Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.20.1. Hemophilia A
12.20.2. Hemophilia B
12.20.3. Von Willebrand Disease
12.20.4. Others
12.21. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.21.1. Recombinant Coagulation Factors
12.21.1.1. Recombinant Coagulation Factor VIII
12.21.1.2. Recombinant Coagulation Factor IX
12.21.1.3. Recombinant Coagulation Factor VIIa
12.21.1.4. Others
12.21.2. Human C1 Esterase Inhibitor
12.22. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.22.1. Chinese Hamster Ovary (CHO) Cell Line
12.22.2. Baby Hamster Kidney (BHK) Cell Line
12.22.3. Human Embryonic Kidney (HEK) Cell Line
12.22.4. Others
12.23. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.23.1. Hemophilia A
12.23.2. Hemophilia B
12.23.3. Von Willebrand Disease
12.23.4. Others
12.24. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.24.1. Recombinant Coagulation Factors
12.24.1.1. Recombinant Coagulation Factor VIII
12.24.1.2. Recombinant Coagulation Factor IX
12.24.1.3. Recombinant Coagulation Factor VIIa
12.24.1.4. Others
12.24.2. Human C1 Esterase Inhibitor
12.25. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.25.1. Chinese Hamster Ovary (CHO) Cell Line
12.25.2. Baby Hamster Kidney (BHK) Cell Line
12.25.3. Human Embryonic Kidney (HEK) Cell Line
12.25.4. Others
12.26. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.26.1. Hemophilia A
12.26.2. Hemophilia B
12.26.3. Von Willebrand Disease
12.26.4. Others
12.27. Rest of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
12.27.1. Recombinant Coagulation Factors
12.27.1.1. Recombinant Coagulation Factor VIII
12.27.1.2. Recombinant Coagulation Factor IX
12.27.1.3. Recombinant Coagulation Factor VIIa
12.27.1.4. Others
12.27.2. Human C1 Esterase Inhibitor
12.28. Rest of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
12.28.1. Chinese Hamster Ovary (CHO) Cell Line
12.28.2. Baby Hamster Kidney (BHK) Cell Line
12.28.3. Human Embryonic Kidney (HEK) Cell Line
12.28.4. Others
12.29. Rest Of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
12.29.1. Hemophilia A
12.29.2. Hemophilia B
12.29.3. Von Willebrand Disease
12.29.4. Others
12.30. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Cell Line
12.30.3. By Indication
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Overview
13.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
13.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.4.1. Recombinant Coagulation Factors
13.4.1.1. Recombinant Coagulation Factor VIII
13.4.1.2. Recombinant Coagulation Factor IX
13.4.1.3. Recombinant Coagulation Factor VIIa
13.4.1.4. Others
13.4.2. Human C1 Esterase Inhibitor
13.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line
13.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.6.1. Chinese Hamster Ovary (CHO) Cell Line
13.6.2. Baby Hamster Kidney (BHK) Cell Line
13.6.3. Human Embryonic Kidney (HEK) Cell Line
13.6.4. Others
13.7. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
13.8. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.8.1. Hemophilia A
13.8.2. Hemophilia B
13.8.3. Von Willebrand Disease
13.8.4. Others
13.9. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis, by Country
13.12. China Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.12.1. Recombinant Coagulation Factors
13.12.1.1. Recombinant Coagulation Factor VIII
13.12.1.2. Recombinant Coagulation Factor IX
13.12.1.3. Recombinant Coagulation Factor VIIa
13.12.1.4. Others
13.12.2. Human C1 Esterase Inhibitor
13.13. China Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.13.1. Chinese Hamster Ovary (CHO) Cell Line
13.13.2. Baby Hamster Kidney (BHK) Cell Line
13.13.3. Human Embryonic Kidney (HEK) Cell Line
13.13.4. Others
13.14. China Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.14.1. Hemophilia A
13.14.2. Hemophilia B
13.14.3. Von Willebrand Disease
13.14.4. Others
13.15. India Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.15.1. Recombinant Coagulation Factors
13.15.1.1. Recombinant Coagulation Factor VIII
13.15.1.2. Recombinant Coagulation Factor IX
13.15.1.3. Recombinant Coagulation Factor VIIa
13.15.1.4. Others
13.15.2. Human C1 Esterase Inhibitor
13.16. India Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.16.1. Chinese Hamster Ovary (CHO) Cell Line
13.16.2. Baby Hamster Kidney (BHK) Cell Line
13.16.3. Human Embryonic Kidney (HEK) Cell Line
13.16.4. Others
13.17. India Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.17.1. Hemophilia A
13.17.2. Hemophilia B
13.17.3. Von Willebrand Disease
13.17.4. Others
13.18. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.18.1. Recombinant Coagulation Factors
13.18.1.1. Recombinant Coagulation Factor VIII
13.18.1.2. Recombinant Coagulation Factor IX
13.18.1.3. Recombinant Coagulation Factor VIIa
13.18.1.4. Others
13.18.2. Human C1 Esterase Inhibitor
13.19. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.19.1. Chinese Hamster Ovary (CHO) Cell Line
13.19.2. Baby Hamster Kidney (BHK) Cell Line
13.19.3. Human Embryonic Kidney (HEK) Cell Line
13.19.4. Others
13.20. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.20.1. Hemophilia A
13.20.2. Hemophilia B
13.20.3. Von Willebrand Disease
13.20.4. Others
13.21. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.21.1. Recombinant Coagulation Factors
13.21.1.1. Recombinant Coagulation Factor VIII
13.21.1.2. Recombinant Coagulation Factor IX
13.21.1.3. Recombinant Coagulation Factor VIIa
13.21.1.4. Others
13.21.2. Human C1 Esterase Inhibitor
13.22. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.22.1. Chinese Hamster Ovary (CHO) Cell Line
13.22.2. Baby Hamster Kidney (BHK) Cell Line
13.22.3. Human Embryonic Kidney (HEK) Cell Line
13.22.4. Others
13.23. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.23.1. Hemophilia A
13.23.2. Hemophilia B
13.23.3. Von Willebrand Disease
13.23.4. Others
13.24. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
13.24.1. Recombinant Coagulation Factors
13.24.1.1. Recombinant Coagulation Factor VIII
13.24.1.2. Recombinant Coagulation Factor IX
13.24.1.3. Recombinant Coagulation Factor VIIa
13.24.1.4. Others
13.24.2. Human C1 Esterase Inhibitor
13.25. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
13.25.1. Chinese Hamster Ovary (CHO) Cell Line
13.25.2. Baby Hamster Kidney (BHK) Cell Line
13.25.3. Human Embryonic Kidney (HEK) Cell Line
13.25.4. Others
13.26. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
13.26.1. Hemophilia A
13.26.2. Hemophilia B
13.26.3. Von Willebrand Disease
13.26.4. Others
13.27. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Cell Line
13.27.3. By Indication
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Overview
14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
14.4.1. Recombinant Coagulation Factors
14.4.1.1. Recombinant Coagulation Factor VIII
14.4.1.2. Recombinant Coagulation Factor IX
14.4.1.3. Recombinant Coagulation Factor VIIa
14.4.1.4. Others
14.4.2. Human C1 Esterase Inhibitor
14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line
14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
14.6.1. Chinese Hamster Ovary (CHO) Cell Line
14.6.2. Baby Hamster Kidney (BHK) Cell Line
14.6.3. Human Embryonic Kidney (HEK) Cell Line
14.6.4. Others
14.7. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
14.8. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
14.8.1. Hemophilia A
14.8.2. Hemophilia B
14.8.3. Von Willebrand Disease
14.8.4. Others
14.9. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis, by Country
14.12. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
14.12.1. Recombinant Coagulation Factors
14.12.1.1. Recombinant Coagulation Factor VIII
14.12.1.2. Recombinant Coagulation Factor IX
14.12.1.3. Recombinant Coagulation Factor VIIa
14.12.1.4. Others
14.12.2. Human C1 Esterase Inhibitor
14.13. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
14.13.1. Chinese Hamster Ovary (CHO) Cell Line
14.13.2. Baby Hamster Kidney (BHK) Cell Line
14.13.3. Human Embryonic Kidney (HEK) Cell Line
14.13.4. Others
14.14. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
14.14.1. Hemophilia A
14.14.2. Hemophilia B
14.14.3. Von Willebrand Disease
14.14.4. Others
14.15. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
14.15.1. Recombinant Coagulation Factors
14.15.1.1. Recombinant Coagulation Factor VIII
14.15.1.2. Recombinant Coagulation Factor IX
14.15.1.3. Recombinant Coagulation Factor VIIa
14.15.1.4. Others
14.15.2. Human C1 Esterase Inhibitor
14.16. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
14.16.1. Chinese Hamster Ovary (CHO) Cell Line
14.16.2. Baby Hamster Kidney (BHK) Cell Line
14.16.3. Human Embryonic Kidney (HEK) Cell Line
14.16.4. Others
14.17. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
14.17.1. Hemophilia A
14.17.2. Hemophilia B
14.17.3. Von Willebrand Disease
14.17.4. Others
14.18. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
14.18.1. Recombinant Coagulation Factors
14.18.1.1. Recombinant Coagulation Factor VIII
14.18.1.2. Recombinant Coagulation Factor IX
14.18.1.3. Recombinant Coagulation Factor VIIa
14.18.1.4. Others
14.18.2. Human C1 Esterase Inhibitor
14.19. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
14.19.1. Chinese Hamster Ovary (CHO) Cell Line
14.19.2. Baby Hamster Kidney (BHK) Cell Line
14.19.3. Human Embryonic Kidney (HEK) Cell Line
14.19.4. Others
14.20. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
14.20.1. Hemophilia A
14.20.2. Hemophilia B
14.20.3. Von Willebrand Disease
14.20.4. Others
14.21. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
14.21.1.1. By Drug Class
14.21.1.2. By Cell Line
14.21.1.3. By Indication
14.21.1.4. PEST Analysis
14.21.1.5. Key Trends
14.21.1.6. Key Developments
15. South America Recombinant Plasma Protein Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Recombinant Plasma Protein Therapeutics Market Overview
15.3. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class
15.4. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
15.4.1. Recombinant Coagulation Factors
15.4.1.1. Recombinant Coagulation Factor VIII
15.4.1.2. Recombinant Coagulation Factor IX
15.4.1.3. Recombinant Coagulation Factor VIIa
15.4.1.4. Others
15.4.2. Human C1 Esterase Inhibitor
15.5. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line
15.6. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
15.6.1. Chinese Hamster Ovary (CHO) Cell Line
15.6.2. Baby Hamster Kidney (BHK) Cell Line
15.6.3. Human Embryonic Kidney (HEK) Cell Line
15.6.4. Others
15.7. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication
15.8. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
15.8.1. Hemophilia A
15.8.2. Hemophilia B
15.8.3. Von Willebrand Disease
15.8.4. Others
15.9. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country
15.10. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Recombinant Plasma Protein Therapeutics Market Analysis, by Country
15.12. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
15.12.1. Recombinant Coagulation Factors
15.12.1.1. Recombinant Coagulation Factor VIII
15.12.1.2. Recombinant Coagulation Factor IX
15.12.1.3. Recombinant Coagulation Factor VIIa
15.12.1.4. Others
15.12.2. Human C1 Esterase Inhibitor
15.13. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
15.13.1. Chinese Hamster Ovary (CHO) Cell Line
15.13.2. Baby Hamster Kidney (BHK) Cell Line
15.13.3. Human Embryonic Kidney (HEK) Cell Line
15.13.4. Others
15.14. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
15.14.1. Hemophilia A
15.14.2. Hemophilia B
15.14.3. Von Willebrand Disease
15.14.4. Others
15.15. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
15.15.1. Recombinant Coagulation Factors
15.15.1.1. Recombinant Coagulation Factor VIII
15.15.1.2. Recombinant Coagulation Factor IX
15.15.1.3. Recombinant Coagulation Factor VIIa
15.15.1.4. Others
15.15.2. Human C1 Esterase Inhibitor
15.16. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
15.16.1. Chinese Hamster Ovary (CHO) Cell Line
15.16.2. Baby Hamster Kidney (BHK) Cell Line
15.16.3. Human Embryonic Kidney (HEK) Cell Line
15.16.4. Others
15.17. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
15.17.1. Hemophilia A
15.17.2. Hemophilia B
15.17.3. Von Willebrand Disease
15.17.4. Others
15.18. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class
15.18.1. Recombinant Coagulation Factors
15.18.1.1. Recombinant Coagulation Factor VIII
15.18.1.2. Recombinant Coagulation Factor IX
15.18.1.3. Recombinant Coagulation Factor VIIa
15.18.1.4. Others
15.18.2. Human C1 Esterase Inhibitor
15.19. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line
15.19.1. Chinese Hamster Ovary (CHO) Cell Line
15.19.2. Baby Hamster Kidney (BHK) Cell Line
15.19.3. Human Embryonic Kidney (HEK) Cell Line
15.19.4. Others
15.20. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication
15.20.1. Hemophilia A
15.20.2. Hemophilia B
15.20.3. Von Willebrand Disease
15.20.4. Others
15.21. South America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Cell Line
15.21.3. By Indication
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. CSL Limited
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Shire Takeda Pharmaceutical Company Limited
16.3.3. Octapharma
16.3.4. Novo Nordisk A/S
16.3.5. Bayer AG
16.3.6. Bioverativ Therapeutics
16.3.7. Aptevo Therapeutics
16.3.8. Pharming Group NV
16.3.9. Pfizer Inc.
16.3.10. Ferring B.V.
16.3.11. Baxter
16.3.12. HEMA Biologics, LLC
16.3.13. OPKO Health, Inc
16.3.14. Sinocelltech Ltd
17. Primary Key Insights